Scarica l'app Stockscreener
5.96
2.23%
0.13
Precedente Chiudi:
$5.83
Aprire:
$5.75
Volume 24 ore:
487.81K
Relative Volume:
0.57
Capitalizzazione di mercato:
$187.27M
Reddito:
$19.09M
Utile/perdita netta:
$-82.13M
Rapporto P/E:
-2.1266
EPS:
-2.8026
Flusso di cassa netto:
$-70.00M
1 W Prestazione:
+16.63%
1M Prestazione:
+18.02%
6M Prestazione:
-54.01%
1 anno Prestazione:
-85.07%
Intervallo 1D:
$5.615
$5.98
Intervallo di 1 settimana:
$5.00
$5.98
Portata 52W:
$4.535
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
5.96 | 146.42M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
Blue Owl Capital Holdings LP Invests $4.30 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research - MarketBeat
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance
LENZ Therapeutics Inc (NASDAQ: LENZ) Share Price, LENZ Stock News, LENZ Share Price & Updates - Kalkine
Q3 EPS Estimate for LENZ Therapeutics Increased by Analyst - MarketBeat
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83 - simplywall.st
Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) - Seeking Alpha
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $7 to $38 - Moomoo
LENZ THERAPEUTICS, INC. : BOFA GLOBAL RESEARCH CUTS TO NEUTRAL FROM BUY; CUTS PRICE OBJECTIVE TO $7 FROM $31 - Bitget
BofA Securities Downgrades LENZ Therapeutics(LENZ.US) to Hold Rating, Cuts Target Price to $7 - Moomoo
BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com Australia
BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo
Why is LENZ Therapeutics stock rallying today? - Investing.com
Why is LENZ Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Cuts Target Price to $7 - Moomoo
LENZ THERAPEUTICS, INC. : CITIGROUP CUTS TARGET PRICE TO $10 FROM $20 - Bitget
LENZ Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside - TradingView
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ... By GuruFocus - Investing.com Canada
Lenz Therapeutics Posts Q2 Revenue Fueled by VIZZ Sales and License Agreements - VisionMonday.com
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: LENZ Therapeutics tops Q2 2026 forecasts as sales jump - Investing.com Nigeria
LENZ Therapeutics Q2 Earnings Call Highlights - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
LENZ Therapeutics Q2 Results: Sales surge 131% vs estimates - scanx.trade
LENZ Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
LENZ: July prescriptions surged 45%+ after telehealth and TV launches, with strong patient persistence - TradingView
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Transcript : LENZ Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com
LENZ Therapeutics (LENZ) grows VIZZ sales but posts $31.9M Q2 loss - Stock Titan
LENZ THERAPEUTICS ($LENZ) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
LENZ Therapeutics Q2 revenue rises on VIZZ sales - TradingView
LENZ Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Over 60% of LENZ’s VIZZ ePharmacy Patients Bought Multiple Packs - Stock Titan
LENZ Therapeutics Inc (LENZ) Q2 2026 Earnings Report Preview: What To Look For - Yahoo Finance
LENZ Therapeutics Inc (LENZ) Q2 2026 Earnings Report Preview: Wh - GuruFocus
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech With A Potential 513% Upside - DirectorsTalk Interviews
LENZ Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
LENZ Therapeutics Inc (LENZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 - marketscreener.com
LENZ Therapeutics Sets Webcast on Its FDA-Approved Eye Drop - Stock Titan
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Hold" from Brokerages - MarketBeat
LENZ|LENZ Therapeutics Inc|Price:5.695|Chg%:+0.215 - TradingKey
LENZ Therapeutics Inc (LENZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lenz Therapeutics Inc Azioni (LENZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 27 '26 |
Buy |
8.95 |
28,089 |
251,411 |
77,289 |
| Chevallard Daniel R. | Chief Financial Officer |
Mar 27 '26 |
Buy |
8.57 |
7,500 |
64,275 |
12,886 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
2.08 |
10,000 |
20,800 |
14,733 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):